CSX Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 18 2025
0mins
Source: Benzinga
Analyst Upgrades: Several top Wall Street analysts have upgraded their ratings on various companies, including Amicus Therapeutics, CSX Corporation, Vale S.A., NIKE, Inc., and Aveanna Healthcare Holdings Inc.
Price Target Changes: Along with the upgrades, analysts have adjusted price targets for these stocks, with notable increases for CSX from $37 to $39 and NIKE from $76 to $90.
Analyst Views on FOLD
Wall Street analysts forecast FOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 15.88 USD with a low forecast of 11.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.380
Low
11.00
Averages
15.88
High
21.00
Current: 14.380
Low
11.00
Averages
15.88
High
21.00
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
